Pharmaceutical companies are making deals related to KRAS inhibitor programs. Jazz Pharmaceuticals has entered into a definitive agreement with Redx Pharma to acquire global rights to the KRAS inhibitor program for over $10 million. Redx Pharma also sold its KRAS program to Jazz Pharmaceuticals for $10 million and earlier sold pan-RAF assets for $3.5 million. Additionally, it sold Jaypirca to Loxo for $40 million. The company had $23 million in the bank as of September 2023. Kazia's lead oncology asset, Paxalisib, is estimated to be worth hundreds of millions, with speculation about who will recognize its value first among Wall Street and several pharmaceutical companies including Merck, Bristol-Myers Squibb, Pfizer, Novartis, Eli Lilly, Roche, GlaxoSmithKline, and AstraZeneca.
$JAZZ joins the KRAS band with $REDX.L deal https://t.co/NFzAHFy6nm
$REDX.L just sold another asset: KRAS programme goes to $JAZZ for $10m. It earlier sold pan-RAF assets to $JAZZ for $3.5m, and famously Jaypirca to $LOXO for $40m. Company had $23m in the bank as of Sep 2023 https://t.co/DNyEMAKI6w
Another KRAS inhibitor deal...this time worth $10m. Includes G12D selective and pan-KRAS molecules $JAZZ $REDX https://t.co/iYpbjLTa9P
$JAZZ & $REDX.LN š®šŖš¬š§ Jazz Pharmaceuticals & RedX Pharma Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program > $10mm upfront https://t.co/wgaC4c29b8 https://t.co/gjVv6eiakx
$KZIA Paxalisib, Kazia's lead oncology asset, is conservatively worth hundreds of millions in all likelihood. The only remaining question is who figures this out first: Wall St, or $MRK $BMY $PFE $NVS $LLY $RHHBY $GSK $JNJ $AZN